Toll Free: 1-888-928-9744

Amunix, Inc. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Amunix, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Amunix, Inc. - Product Pipeline Review - 2014', provides an overview of the Amunix, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amunix, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Amunix, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Amunix, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Amunix, Inc.'s pipeline products

Reasons to buy

- Evaluate Amunix, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Amunix, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Amunix, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Amunix, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amunix, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Amunix, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Amunix, Inc. Snapshot 5
Amunix, Inc. Overview 5
Key Information 5
Key Facts 5
Amunix, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Amunix, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Amunix, Inc. - Pipeline Products Glance 13
Amunix, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Amunix, Inc. - Drug Profiles 15
AMX-256 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
coagulation factor IX (recombinant) 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
coagulation factor VIIa (recombinant) 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
enfuvirtide 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Recombinant Protein-1 for Undisclosed Indication 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Recombinant Protein-2 for Undisclosed Indication 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Recombinant Protein-4 for Undisclosed Indication 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Recombinant Protein-5 for Undisclosed Indication 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Recombinant Protein-6 for Undisclosed Indication 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
T20-XTEN Conjugates 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
AMX-179 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Recombinant Protein-3 for Undisclosed Indication 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Recombinant Protein-7 for Undisclosed Indication 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Recombinant Protein-8 for Undisclosed Indication 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Amunix, Inc. - Pipeline Analysis 30
Amunix, Inc. - Pipeline Products by Target 30
Amunix, Inc. - Pipeline Products by Route of Administration 31
Amunix, Inc. - Pipeline Products by Molecule Type 32
Amunix, Inc. - Pipeline Products by Mechanism of Action 33
Amunix, Inc. - Recent Pipeline Updates 34
Amunix, Inc. - Dormant Projects 35
Amunix, Inc. - Locations And Subsidiaries 36
Head Office 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38
List of Tables
Amunix, Inc., Key Information 5
Amunix, Inc., Key Facts 5
Amunix, Inc. - Pipeline by Indication, 2014 8
Amunix, Inc. - Pipeline by Stage of Development, 2014 9
Amunix, Inc. - Monotherapy Products in Pipeline, 2014 10
Amunix, Inc. - Out-Licensed Products in Pipeline, 2014 11
Amunix, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 12
Amunix, Inc. - Preclinical, 2014 13
Amunix, Inc. - Discovery, 2014 14
Amunix, Inc. - Pipeline by Target, 2014 30
Amunix, Inc. - Pipeline by Route of Administration, 2014 31
Amunix, Inc. - Pipeline by Molecule Type, 2014 32
Amunix, Inc. - Pipeline Products by Mechanism of Action, 2014 33
Amunix, Inc. - Recent Pipeline Updates, 2014 34
Amunix, Inc. - Dormant Developmental Projects,2014 35 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify